Eye on Pharma: Similis Bio Launch, Biocon Biologics Sets Sights on Malaysian Biosimilar Market

May 19, 2022

New biosimilars are on the way, as JSR Life Sciences launches its business division (Similis Bio) that will improve efficiency and costs related to biosimilar development and Biocon Biologics signs a contract for commercialization in Malaysia.

Dr Eric Tichy Calls for Government Officials to Realign Incentives in Favor of Biosimilars

May 18, 2022

Teva’s Lucentis Biosimilar Gains UK Approval

May 17, 2022

Contributor: No Good Deed Goes Unpunished—How PBM Mandates Increase Practice Variability

May 17, 2022

Alvotech Announces Positive Phase 1 Results for Ustekinumab Biosimilar

May 16, 2022

Featured Content

Medicare Policies Must Fix Cost Sharing Under Part D, Expert Writes

Stacie B. Dusetzina, PhD, is the Ingram Associate Professor of Cancer Research at Vanderbilt University Medical Center, and a member of the editorial board for The American Journal of Managed Care®.

a bunch of healthcare related clip art images interconnected

Opinion: Efforts to Improve Biosimilars Education Are a Start, but Payer Policies Must Catch Up

Despite improvements in biosimilar education efforts for future health care professionals, payer policies need a major revamp to ensure that biosimilar use is encouraged, according to Pfizer's Mike Gladstone.

New House Bill Could Expand User Fee Programs for Biosimilars

A new bill that would amend the Federal Food, Drug, and Cosmetic Act aims to expand FDA user fee programs for prescription drugs and medical devices, including biosimilars and generics.

Pfizer Settles 2 Lawsuits, Starts Another Over Etanercept Biosimilar in Australia

May 16th 2022

By Skylar Jeremias

Article

After agreeing to settle with Amgen over its oncology biosimilars, Pfizer issued a new patent lawsuit against 5 companies over the development of Brenzys, an etanercept biosimilar, in Australia.

Julie Reed Talks About How Savings Can Differ Between Patients, Health Plans

May 14th 2022

By Skylar Jeremias

Video

Julie M. Reed, the executive director of the Biosimilars Forum, discusses how biosimilar savings can differ between stakeholders and the importance of competition for creating those savings.

Conference Posters Highlight Real-world Trends of Biosimilars, Reclassified Biologics

May 14th 2022

By Skylar Jeremias

Article

Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting examined the real-world patterns of biosimilar utilization and the impact of products that have been reclassified as biologics on Medicaid spending.

The Top 5 Biosimilar Articles for the Week of May 9

May 13th 2022

By Skylar Jeremias

Article

Here are the top 5 biosimilar articles for the week of May 9, 2022.

New House Bill Could Expand User Fee Programs for Biosimilars

May 12th 2022

By Skylar Jeremias

Article

A new bill that would amend the Federal Food, Drug, and Cosmetic Act aims to expand FDA user fee programs for prescription drugs and medical devices, including biosimilars and generics.

Biocon Revenue Up 21% Thanks to Biosimilar, Generic Drug Successes

May 11th 2022

By Skylar Jeremias

Article

Biocon’s total revenue for the fourth quarter of the 2022 fiscal year was up 21% from the same period in the prior year, largely due to significant growth in sales for the company’s biosimilar and generic drugs.

Health IT for Biosimilars Spotlight: Cardinal Health's Decision Pathway

May 10th 2022

By Skylar Jeremias

Video

Amy Valley, vice president of clinical strategy and technology solutions at Cardinal Health, details the company's Decision Pathway, a health information technology (IT) tool that can assist practices with prescribing patients the lowest-cost product, including biosimilars.

Contributor: The Enemy of Your Enemy Should Be Your Friend – Why Biosimilars Companies Should Collaborate

May 9th 2022

By Ivo Abraham, PhD

Article

Biosimilar manufacturers should consider working together to overcome some of the barriers that prevent biosimilars from entering the market and obtaining market share, according to Ivo Abraham, PhD, chief scientist of Matrix45 and a member of The Center for Biosimilars® Advisory Board.

Dr Sonia Oskouei Describes the Need for More Biosimilar Education for Ophthalmologists

May 8th 2022

By Skylar Jeremias

Video

Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Cardinal Health's Sonia T. Oskouei, PharmD, BCMAS, DPLA.

Amgen Biosimilars See Increased Sales as Reference Product Sales Erode

May 7th 2022

By Skylar Jeremias

Article

Amgen’s earnings report for the first quarter of 2022 reveals that as some of its biosimilars experienced increased sales, its sales for reference products that are facing biosimilar competition decreased.